Welcome to NGN-Captial

	NGN BioMed Opportunity I
	NGN BioMed Opportunity II

	Profile
	Portfolio
	Contact Us

	General Partners
	Partners
	Principals
	C.F.O.
	Venture Partners
	Senior Advisors

	Advisory Board

	Email Us
	US Offices
	European Office

	Profile
	Our Team
	The Location
	Contact Us

	Civil Law
	Law of Succession Family Law
	Intellectual Property
	Commercial Law Corporate Law
	Real Estate
	Foreclosure Insolvency Forced Sale
	Labour Law
	Criminal Law
	International Law Community Law

	Relocation

	Network Solutions
	E-Business
	Internet
	Web Design

Press Releases

Horizon Therapeutics and Nitec Pharma Complete Merger and Combine Businesses
Nitec Pharma reports positive and highly significant phase III results from Capra-2 study of Lodotratm™ in RA
Nitec Announces First Launch Of Lodotra® In Germany
Nitec Pharma Grants Exclusive European Distribution Licence To Mundipharma For Lodotra™
Jerini AG and Shire Limited Announce Strategic Partnership
ACT Biotech Acquires Clinical And Early Stage Oncology Portfolio Licenses From Bayer Healthcare
Artisan Pharma, Inc. Raises $39 Million in a Series A Financing Led by NGN Capital LLC
Micromet Announces Definitive Agreement for $8.0 Million Private Placement (Press Release Source: Micromet Inc.)
NGN Capital Joins With The Carlyle Group To Complete The Acquisition of MultiPlan, Nation’s Largest Independent PPO
NGN Capital Led Syndicate Participates In Selling Sightline Technologies Ltd. To Stryker Corporation
NGN Capital co-leads a $42.2 million Series B financing in Small Bone Innovations, Inc.
NGN Capital leads $32 Million PIPE in Javelin Pharmaceuticals
NGN Capital Closes its First Healthcare Venture Capital Fund at $250 million
Nitec Pharma AG closes CHF 32 million (approx. US$ 26 million) Series B financing led by NGN Capital

Additional Portfolio Company Articles

Top of Page

Print Version